|
Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China’s production-use plasma volume broke through 4,000 tons and the total lot release volume jumped by 15% year on year to 52.4 million bottles in 2014. By lot release volume, human albumin, human rabies immunoglobulin, human immunoglobulin (ph4) for intravenous injection and tetanus immunoglobulin were the most popular blood products in China in 2014, accounting for 59.8%, 14.6%, 13.6% and 4.1% of the total lot release volume respectively. At the same time, the supply and R & D capabilities of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand have been intensified in recent years. In 2014, the lot release volume of the above two products ascended by 43.9% and 46.3% year on year respectively. Chengdu Rongsheng, Guangdong Danxia, Yuanda Shuyang, Shanxi Kangbao and other enterprises obtained clinical approval for their human blood coagulation factor VIII in 2014. Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.3% to China’s production-use plasma volume and 33.6% to China’s blood product revenue in 2014. Shanghai RAAS turns to be a Chinese blood product leader through two acquisitions. In 2014, it took over Banghe Pharmaceutical (now known as Zhengzhou RAAS) and TONROL for RMB1.8 billion and RMB4.758 billion separately, so that the blood product varieties of the company increased from 7 to 11, the number of plasma collection stations rose from 12 to 28, and its plasma collection capacity expanded from 400 tons to 900 tons. China Blood Product Industry Report, 2015-2018 focuses on the followings: Market characteristics, operating environments, status quo, etc. of China blood product industry;
Supply and demand, competitive landscape, import & export, development forecast, etc. of China blood product industry;
Supply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin.
Operation, blood product business and development prospects of 12 major Chinese blood product companies.
|
Login
Location : 
